Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
3 AI Stocks That Could Make You a Fortune (If You Dare) | news.google.com • |
Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average of $0.39 | news.google.com • |
Is Now An Opportune Moment To Examine Daré Bioscience, Inc. (NASDAQ:DARE)? | news.google.com • |
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript | seekingalpha.com • |
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 | globenewswire.com • |
Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript | seekingalpha.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -0.06 | N/A | N/A | N/A |
2024-03-28 | 2023-12 | -0.12 | -0.06 | 0.06 | 50.00% |
2023-11-09 | 2023-09 | -0.1 | -0.09 | 0.01 | 10.00% |
2023-08-10 | 2023-06 | -0.1 | -0.1 | N/A | N/A |
2023-05-11 | 2023-03 | -0.1 | -0.09 | 0.01 | 10.00% |
2023-03-30 | 2022-12 | -0.15 | -0.19 | -0.04 | -26.67% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-06-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-05-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-30 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-10-02 | ARBUCKLE STUART A | Director | 5.64K | Stock Award(Grant) |
2017-01-02 | FRIEDMAN PAUL A | Director | 8.55K | Stock Award(Grant) |
2016-12-29 | GUIFFRE CHRISTOPHER D T | Chief Executive Officer | 12.49K | Stock Award(Grant) |
2019-04-10 | HAWLEY ROGER L | Director | 0.00 | Purchase |
2017-07-18 | JOHNSON SABRINA MARTUCCI | Chief Executive Officer | 0.00 | Stock Award(Grant) |
2017-01-02 | MCKEE WILLIAM T | Director | 3.42K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 3.44M | 3.13M | 3.92% |
2023-06-29 | Geode Capital Management, LLC | 817.34K | 743.86K | 0.93% |
2023-06-29 | Renaissance Technologies, LLC | 718.82K | 654.20K | 0.82% |
2023-06-29 | Blackrock Inc. | 416.06K | 378.66K | 0.47% |
2023-06-29 | State Street Corporation | 247.71K | 225.44K | 0.28% |
2023-06-29 | Susquehanna International Group, LLP | 164.02K | 149.28K | 0.19% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.38M | 2.16M | 2.71% |
2023-06-29 | Vanguard Extended Market Index Fund | 942.15K | 857.45K | 1.07% |
2023-05-30 | Fidelity Extended Market Index Fund | 446.55K | 451.02K | 0.51% |
2023-05-30 | Fidelity Total Market Index Fund | 186.90K | 188.76K | 0.21% |
2023-08-30 | iShares Micro Cap ETF | 187.65K | 128.41K | 0.21% |
2023-06-29 | Price (T.Rowe) U.S. Equities Trust | 125.90K | 114.58K | 0.14% |
Split | Date |
---|---|
1 : 10 | 2017-07-20 |
-
Useless CEO
-
Dare Bioscience Stock (NASDAQ:DARE), Analyst Ratings, Price Targets, Predictions
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.Consensus Rating1
Buy
Highest Price Target1
$11.00
Lowest Price Target1
$6.00
Consensus Price Target1
$7.88
Analyst Rating Summary1
Buy Overweight Hold Underweight Sell 4 0 0 0 0
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JonesTrading
Roth Capital
Brookline Capital1calculated from analyst ratings published within the last 3 years
ANALYST RATINGS FOR DARE BIOSCIENCE
All Ratings (7)
Upgrades (0)
Downgrades (0)
Initiations (3)
Premium Tools & IdeasDate
Upside/Downside
Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/31/2023 621.28% HC Wainwright & Co. → $7 Reiterates → Buy Get Alert
12/13/2022 621.28% HC Wainwright & Co. $6 → $7 Maintains Buy Get Alert
12/01/2022 518.24% JonesTrading → $6 Initiates → Buy Get Alert
04/01/2022 518.24% HC Wainwright & Co. $5 → $6 Maintains Buy Get Alert
06/30/2021 1033.44% Roth Capital $9 → $11 Maintains Buy Get Alert
12/18/2020 415.2% HC Wainwright & Co. → $5 Initiates → Buy Get Alert
04/28/2020 672.8% Brookline Capital -
Analyst Forecast
According to 12 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $6.12, which is an increase of 530.86% from the latest price.Price Target
$6.12
(530.86% upside)
Analyst Consensus: BuyStrongSell
Sell
Hold
Buy
StrongBuy
0
5
10 -
Is dare will get any benefit from abortion pill ban ?
-
Accomplishments:
License Agreement with Organon to Commercialize XACIATOTM
Ovaprene IDE Approval for Pivotal Contraceptive Efficacy Study
Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1
Three Additional Portfolio Programs (DARE-PDM1, DARE-GML and grant-funded DARE-LBT)
2023 Anticipated Milestones:XACIATO First Commercial Sale
Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Topline Data
Ovaprene Pivotal Contraceptive Efficacy Study Initiaton
DARE-PDM1 Phase 1 Study Topline Data
IND and Clinical Study Initiation Activities for DARE-VVA1 and DARE-HRT1
SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.“Daré announced a number of positive developments related to our existing portfolio since the beginning of 2022 which serve to benefit all of our stakeholders. We entered into an exclusive global license agreement with Organon for commercialization of our first FDA-approved product, XACIATO. We completed two Phase 1/2 clinical studies in Australia and announced positive topline data for both. We received FDA approval of our IDE application for Ovaprene, allowing us to conduct a single arm, open-label pivotal contraceptive efficacy study and we hosted an investigator meeting. Finally, we completed subject screening for our exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% for female sexual arousal disorder and are targeting the second quarter of 2023 to announce topline data. We seek to continue the progress made over the past fifteen months by moving these candidates forward in development in 2023 and 2024,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
-
Analyst Forecast
According to 12 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $6.12, which is an increase of 494.18% from the latest price.Price Target
$6.12
(494.18% upside)
Analyst Consensus: BuyStrongSell
Sell
Hold
Buy
StrongBuy
0
5
10 -
-
Xaciato is a Vaginal Anti-infectives class drug manufactured by ORGANON. The average counter price of Xaciato is $202.99 per 1, 5GM of 2% Gel, but you can pay only $151.22 for 1, 5gm of 2% Tube of generic Xaciato with a SingleCare prescription drug discount card to use the generic Xaciato coupon.
https://www.singlecare.com › xaciato
Xaciato Coupons 2023: Up to 80% Discount - SingleCare -
Dare Bioscience Stock (NASDAQ:DARE), Analyst Ratings, Price Targets, Predictions
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.Consensus Rating1
Buy
Highest Price Target1
$7.00
Lowest Price Target1
$6.00
Consensus Price Target1
$6.50
Analyst Rating Summary1
Buy Overweight Hold Underweight Sell 2 0 0 0 0 -
Analyst Forecast
According to 10 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 521.88% from the latest price.Price Target
$5.1
(521.88% upside)
Analyst Consensus: BuyStrongSell
Sell
Hold
Buy
StrongBuy
0
5
10 -
Daré Bioscience, Inc. Announces Global Licensing Rights To The Novel Antimicrobial Glycerol Monolaurate For Vaginal Health
Mentioned: DARE
Darà Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Darà acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of vaginal health conditions including bacterial, fungal, and viral infections. -
DARÉ BIOSCIENCE CONSENSUS RATING AND PRICE TARGET (2022)How MarketBeat Calculates Price Target and Consensus Rating
CONSENSUS ANALYST RATING
BUY
Based on 3 Analyst Ratings
CONSENSUS ANALYST PRICE TARGET
$9.00
620.00% Upside
High Prediction $17.00
Average Prediction $9.00
Low Prediction $4.00 -
Analyst Forecast
According to 10 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 4.85, which is an increase of 340.91% from the latest price.Price Target
$4.85
(340.91% upside)
Analyst Consensus: Buy
ChartBar chart with 5 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0 to 7.StrongSell
Sell
Hold
Buy
StrongBuy
0
5
10 -
Analyst Forecast
According to 11 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 4.85, which is an increase of 284.92% from the latest price.Price Target
$4.85
(284.92% upside)
Analyst Consensus: Buy
ChartBar chart with 5 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0 to 8.Stron
-
Analyst Forecast
According to 11 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 7.34, which is an increase of 439.71% from the latest price.Price Target
$7.34
(439.71% upside)
Analyst Consensus: Buy -
Analyst Forecast
According to 11 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 7.34, which is an increase of 487.20% from the latest price.Price Target
$7.34
(487.20% upside)
Analyst Consensus: Buy -
Analyst Forecast
According to 11 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 7.34, which is an increase of 501.64% from the latest price.Price Target
$7.34
(501.64% upside)
Analyst Consensus: Buy -
Analyst Forecast
According to 11 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 7.34, which is an increase of 599.05% from the latest price.Price Target
$7.34
(599.05% upside)
Analyst Consensus: Buy -
Average Analyst Ratings
3 MTHS AGO
Strong Buy
5.00
Based on 5 analysts
2 MTHS AGO
Strong Buy
5.00
Based on 6 analysts
1 MTH AGO
Strong Buy
5.00
Based on 5 analysts
CURRENT
Strong Buy
5.00
Based on 5 analysts
RATINGS VALUES: Strong Buy = 5 Moderate Buy = 4 Hold = 3 Moderate Sell = 2 Strong Sell = 1
Ratings Breakdown
3 MTHS AGO
Strong Buy
Based on 5 analysts
5 Strong Buy
2 MTHS AGO
Strong Buy
Based on 6 analysts
6 Strong Buy
-
3 AI Stocks That Could Make You a Fortune (If You Dare)
news.google.com • -
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
Daré Bioscience's 'female Viagra' could be first-in-category product: broker
proactiveinvestors.com • -
Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript
seekingalpha.com • -
Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
Daré Bioscience to Present at the 35th Annual Roth Conference
globenewswire.com • -
Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Daré Bioscience to Participate in Two Upcoming Conferences
globenewswire.com • -
Good Penny Stocks to Buy Now? 3 to Watch in June
pennystocks.com • -
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
globenewswire.com • -
Trading Penny Stocks? Top Stock Market News for March 31st, 2022
pennystocks.com • -
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
globenewswire.com • -
Daré Bioscience to Participate in Upcoming Conferences
globenewswire.com • -
4 Penny Stocks To Buy For Under $4 Right Now
pennystocks.com • -
These Penny Stocks Climbed Today, Here's Why
pennystocks.com • -
Dare Bioscience Stock (DARE): Why The Price Surged
pulse2.com • -
3 Reddit Penny Stocks For Your Early December Watchlist
pennystocks.com • -
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
globenewswire.com • -
Best Penny Stocks To Buy Now? 3 To Watch As AMC Stock Sparks Rally
pennystocks.com • -
Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?
pennystocks.com • -
3 Penny Stocks on Reddit That Traders Are Buying Right Now
pennystocks.com • -
Best Penny Stocks to Buy? 3 to Watch In the Second Half of 2021
pennystocks.com • -
Top Penny Stocks to Watch to Start Your Week Off Right
pennystocks.com • -
High Volume Penny Stocks to Watch After The Market Crash
pennystocks.com • -
Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List
pennystocks.com • -
DARE Stock: Why Did ‘Gates' Give Dare Bioscience a $49M Grant?
investorplace.com • -
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
pennystocks.com • -
Dare Bioscience: Q4 Earnings Insights
benzinga.com • -
Daré Bioscience to Participate in Upcoming Virtual Conferences
globenewswire.com • -
DARE Stock: Why Daré Bioscience Is on the Move Today
investorplace.com • -
40 of the best Prime Day deals for day 2
androidcentral.com • -
The 18 best Amazon device deals on Prime Day: Echo, Ring Doorbell, and more
androidcentral.com • -
Prime deals 2020: All the best deals from day one of Prime Day
androidcentral.com • -
Ring Energy Approaches Its Next Borrowing Base Redetermination (NYSEMKT:REI)
seekingalpha.com • -
Comparing Medicure (OTCMKTS:MCUJF) & Dare Bioscience (OTCMKTS:DARE)
thelincolnianonline.com • -
Dare Bioscience (NASDAQ:DARE) Stock Rating Lowered by ValuEngine
thelincolnianonline.com • -
3 “Strong Buy” Penny Stocks That Could Deliver Massive Returns
finance.yahoo.com • -
Investing in Nanotechnology Stocks and Companies
nanalyze.com • -
Dare Bioscience (NASDAQ:DARE) Stock Rating Reaffirmed by Maxim Group
thelincolnianonline.com • -
Citizens protest Hancock County sheriff’s request for riot gear
pressherald.com • -
Can Your Depression Medication Affect Your Sex Life?
huffpost.com •